Skip to main content

Table 3 Intragroups comparation of laboratory tests before (week 0) and after treatment (week 16)

From: A 16-week study to compare the effect of vildagliptin versus gliclazide on postprandial lipoprotein concentrations and oxidative stress in patients with type 2 diabetes inadequately controlled with metformin monotherapy

Parameters

Gliclazide

Vildagliptin

Week 0

Week 16

P

Week 0

Week 16

P

Insulin (pg/mL)

716 ± 316.7

819.7 ± 391.9

0.160

705.59 ± 468.8

599.6 ± 417.7

0.021

Glucagon (pg/mL)

79.1 ± 43.1

77.7 ± 40.0

0.921

65.2 ± 36.1

46.6 ± 30.8

0.004

A1c (%)

9.2 ± 1.2

6.9 ± 1.1

0.000

8.7 ± 0.9

6.9 ± 0.9

0.000

C-peptide (pg/mL)

1882.0 ± 690.1

2092.8 ± 956.2

0.193

1627.2 ± 585.6

1622.6 ± 609.6

0.059

GLP-1 pg/mL)

38.3 ± 25.3

45.5 ± 21.1

0.218

44.7 ± 38.7

83.8 ± 74,5

0.026

GIP (pg/mL)

39.1 ± 15.2

45.6 ± 39.0

0.201

38.9 ± 25.7

44.7 ± 34.8

0.405

TBAR (nmolMDA/mL)

8.9 ± 1.4

8.47 ± 0.9

0.262

9.0 ± 1.6

8.0 ± 0.7

0.035

TAOS

215.9 ± 34.5

264.3 ± 34.0

0.179

257.5 ± 61.3

205.3 ± 28.2

0.417

  1. Data are means ± SD. GLP-1, Glucagon like peptide 1; GIP Gastric inhibitory polypeptide, TBARS Thiobarbituric Acid reactive substances, TAOS antioxidant state